Date: Monday 23 June
Time: 10.00am - 11.15am

Overview

This session will explore the use of biomarker technology to support  the diagnostic assessment of patients with Alzheimer’s disease (AD) in clinical practice.

Dr Chineze Ivenso (Consultant Old Age Psychiatrist at Aneurin Bevan University Health Board, Newport, Wales, and Academic Secretary, Faculty of Old Age Psychiatry, Royal College of Psychiatrists) will present on the development of memory assessment services in Wales, which offer in-house access to biomarker investigations.

Professor Paresh Malhotra (Consultant Neurologist at Imperial College Healthcare NHS Trust and Head of the Division of Neurology at Imperial College London) will present on Implementing Alzheimer’s biomarkers in the NHS: The Imperial Amyloid PET cohort. He will discuss the implementation of Amyloid PET imaging at Imperial College healthcare NHS Trust, where over 500 patients have had clinical amyloid PET imaging over the last decade. Aspects of his talk will cover the use of appropriate use criteria to guide our MDT approach, better understanding of the spectrum of Alzheimer’s presentations through systematic evaluation of this patient cohort, and how their experience might inform the introduction of blood-based biomarker technologies.

Dr Jemma Hazan (Consultant Old Age Psychiatrist and Alzheimer’s Research UK Clinical Fellow, UCL) will focus on the application of AD blood biomarkers in Memory services. She will present on the ADAPT: Alzheimer’s disease Diagnosis And Plasma P-Tau217 Study, a national randomised controlled trial to determine the real-life clinical utility and cost-effectiveness of this blood biomarker in memory services.

This session with be chaired by Professor Robert Howard (Consultant Old Age Psychiatrist at the North London NHS Foundation Trust and Professor of Old Age Psychiatry, Division of Psychiatry). He will offer insights into the future directions of AD blood biomarker in diagnostic assessments.

In this session you will:

• Explore the development of memory services that provide access to Alzheimer's disease biomarker investigations, such as cerebrospinal fluid analysis, FDG PET, and Amyloid PET scans
• Learn about the appropriate use and implementation of amyloid-PET in real-world clinical settings and how this may inform the introduction of blood-based biomarker technologies
• Gain insights into the evaluation of the clinical utility of Alzheimer's disease blood biomarkers in memory services

Speakers

Chair: Professor Robert Howard, UCL, London

The development of memory assessment services in Wales, which offer in-house access to biomarker investigations

Dr Chineze Ivenso, Aneurin Bevan University Health Board, Newport

Implementing alzheimer’s biomarkers in the NHS: the imperial amyloid PET cohort

Professor Paresh Malhotra, Imperial College London, Imperial College Healthcare NHS Trust, London

ADAPT: Alzheimer’s disease diagnosis and plasma p-Tau217

Dr Jemma Hazan, UCL, London